StockMirror — Stock Screener

APLLTD Q2 FY27 Results & Earnings Analysis

Sentiment: Great (Confidence: high)

Earnings Summary

Alembic Pharmaceuticals delivered strong Q2 FY27 with 36% YoY revenue growth to INR2,603 crores, 78% EBITDA growth, and 81% PAT growth, driven by U.S. generics (72% YoY), API (39% YoY), and India recovery (11% YoY). EBITDA margin expanded 520 bps YoY to 22.2%. Management raised FY27 revenue growth guidance to 20-25% from mid-teens, expects H2 margins to hold ~22%, and targets ~20% EBITDA margin in FY28/29 with U.S. branded breakeven by H1 FY28. DifGen collaboration adds 20+ complex generics for future growth. Balance sheet healthy with net debt <1x EBITDA.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management raised revenue guidance and emphasized margin expansion through operating leverage and U.S. branded breakeven, while continuing R&D and pipeline investments.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited (APLLTD) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More